Loading…
BBLG
Bone Biologics Corp
NASDAQ· Healthcare· Biotechnology· CUSIP 098070600
$0.62-0.03%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $1.69M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.3x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.28
- ROE
- -54.96%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.53
- 52-week high
- $4.13
- 52-week low
- $0.58
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.45 | $5.64 | $27.12 | $302.40 | |
| P/B | 0.7x | 0.5x | 0.8x | 0.8x | 0.5x |
| EPS | -$2.65 | -$28.96 | -$204.06 | -$186.90 | |
| ROE | -87.93% | -57.81% | -118.05% | -307.90% | -24.96% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SCNIScinai Immunotherapeutics Ltd. | $2.51 | 0.1x | 0.1x | — | -26.53% | $1.7M |
| AEMDAethlon Medical Inc | $2.49 | — | 0.2x | — | -160.91% | $1.77M |
| SXTCChina SXT Pharmaceuticals, Inc. | $3.00 | — | 0.1x | — | -27.49% | $1.6M |
| MNDRMobile-health Network Solutions | $1.55 |
About the company
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
- 2
- Burlington, United States
Company description provided by Yahoo Finance.